Hydromorphone Hydrochloride and Pregnancy
Links shared publicly online about this topic
Lannett Receives FDA Approvals For Hydromorphone Hydrochloride Tablets USP, 2 Mg, 4 Mg And 8 Mg Strengths
medicalnewstoday.com — “Lannett Company, Inc. (NYSE AMEX: LCI) announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone ” View full resource at medicalnewstoday.com
Most Recently Shared on December 13, 2009 at 5:17 pm By:
MNT Pain News Pain Management and Health News
Lannett Receives FDA Approvals For Hydromorphone Hydrochloride Tablets USP, 2 Mg, 4 Mg And 8 Mg Strengths: Lannett ... http://bit.ly/8z1G3e
Akorn, Inc. Announces FDA Approval For Hydromorphone Hydrochloride Injection 10mg/ml In 1ml, 5ml And 50ml Doses
medicalnewstoday.com — “Akorn, Inc. (NASDAQ: AKRX) a niche generic pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application” View full resource at medicalnewstoday.com
Most Recently Shared on April 18, 2010 at 12:05 pm By:
MNT Pharma News Health News and Pharma
Akorn, Inc. Announces FDA Approval For Hydromorphone Hydrochloride Injection 10mg/ml In 1ml, 5ml And 50ml Doses http://mnt.to/3Bnx
Bulletin
ashp.org — “Bulletin” View full resource at ashp.org
Most Recently Shared on December 22, 2011 at 6:58 am By:
HospiScript Services Health Organization
December 21st Release- Hydromorphone Hydrochloride Low Potency Injection Shortage http://t.co/flrcFNeg
Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.
news-medical.net — “Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation o” View full resource at news-medical.net
Most Recently Shared on August 11, 2010 at 10:45 am By:
Pregnancy News: Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.: Labopharm Inc. to... http://bit.ly/9JufSO
Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. -- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg.” View full resource at news-medical.net
Most Recently Shared on December 15, 2010 at 12:09 pm By:
Medicare News: Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt: Watson Pharmaceuti... http://bit.ly/f0gFg0
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Pain News
The latest pain and anesthetics news published daily. Articles from research centers, universities and prestigious journals.
-
MNT Pharma News
The latest pharma industry news published daily. Articles from research centers, universities and prestigious journals.
-
HospiScript Services
Beyond Prescription Benefits Management, HospiScript partners with hospices to provide reduced drug costs, expert clinical support & educational opportunities.
Advertisement
